Acne Drug Switch Study Stirs FDA Doubts About Pregnant Women's Self-Selection
This article was originally published in The Tan Sheet
The NDAC met April 15 to make recommendations on Galderma's first-in-class switch proposal for adapalene gel 0.1% indicated for treatment of acne in consumers ages 12 and older. FDA told the committee Galderma's study did not "demonstrate that pregnant or breastfeeding women could adequately self-select to use the product."
You may also be interested in...
CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.